课题基金 / 基金详情

Glial versus Neuronal Caspase-3 in Opioid-HIV gp120 Neurotoxicity

Glial versus Neuronal Caspase-3 in Opioid-HIV gp120 Neurotoxicity
阿片类药物-HIV gp120 神经毒性中的胶质细胞与神经元 Caspase-3
批准号:
8263482
负责人:
Kimberly Lynne Samano
金额:
$4.04万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-25 至 2014-05-24

项目摘要

项目成果

Kimberly Lynne Samano的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):HIV-1是一种全球性流行病,主要通过性接触和使用注射药物(如海洛因)传播。自20世纪90年代中期实施cART(联合主动抗逆转录病毒疗法)以来,感染HIV-1和AIDS的个体的寿命更长,这增加了与HIV-1相关的神经和心理特征。总的来说,这些CNS缺陷被称为HIV-1相关的神经认知障碍(HAND),包括HIV相关的痴呆(HAD)和HIV相关的脑炎(HIVE)。广义而言,HAND综合征的特征是认知、运动和行为功能障碍;提示基底神经节功能障碍[7,34,42,75]。结合患者的高病毒载量,基底神经节内的纹状体区域优先具有高丰度的μ阿片受体(莫尔)表达[24]。已知阿片类药物可调节免疫功能,这种混淆可能会加重HIV-1的发病机制和神经系统并发症[20,44 - 6,66,74]。 HIV-1的病毒外壳糖蛋白gp 120是病毒进入和感染所需的已确定的神经毒素,其细胞外作用在体外和体内对神经元和神经胶质细胞(小胶质细胞和星形胶质细胞)具有毒性 在人类和啮齿动物模型中[4,5,9,11,12,15,17,19,35,50,51,60,61,70]。我们的实验室和其他人已经证明了阿片类药物如何增强这种gp 120诱导的神经毒性[1,28,45]。我们已经证明,gp 120增加半胱天冬酶-3活性,并诱导纹状体神经元凋亡。我们有兴趣更好地了解阿片类药物如何影响HIV-gp 120诱导的纹状体内的神经毒性,特别是要研究caspase-3在神经胶质细胞和神经元介导的神经毒性机制中的作用。研究提出,以确定是否胶质细胞caspase-3介导的gp 120神经毒性1阿片类药物,并建立是否阿片类药物通过caspase-3直接影响神经元损伤和/或死亡,在体外使用caspase-3敲除细胞。最后,我们将使用caspase-3基因敲除小鼠来研究执行者caspase的全基因组缺失将如何影响体内gp 120 1阿片类药物后的神经胶质细胞和神经元反应。总的来说,拟议的研究将增加对caspase-3如何在gp 120和阿片类药物在HIV神经发病机制方面的相互作用中发挥作用的理解。有了这些信息,就有可能更好地了解潜在的机制,从而产生新的治疗选择,这对阿片类药物滥用者和感染HIV-1的使用者产生了影响。 公共卫生相关性:艾滋病毒阳性阿片类药物滥用者加速发展为艾滋病,由于受感染者在目前的抗逆转录病毒治疗下寿命更长,因此与艾滋病毒相关的神经认知障碍,包括痴呆症的发病率增加。我们的研究将有助于确定潜在的治疗药物,用于预防和治疗使用和/或滥用阿片类药物的HIV阳性个体的神经认知功能障碍。
英文摘要
DESCRIPTION (provided by applicant): HIV-1 is a global epidemic spread predominantly through sexual contact and through the use of injectable drugs, such as heroin. Since the implementation of cART (Combined Active Antiretroviral Therapy) in the mid 1990's, infected individuals are living longer with HIV-1 and AIDS, which augments the neurological and psychological profiles associated with HIV-1. Collectively, these CNS deficits are known as HIV-1 associated neurocognitive disorders (HAND) and include HIV-associated dementia (HAD) and HIV-associated encephalitis (HIVE). Broadly, HAND syndromes are characterized by cognitive, motor and behavior dysfunctions; indicative of basal ganglia dysfunction [7,34,42,75]. In conjunction with high viral load in patients, the striatal region within the basal ganglia preferentially has a high abundance of mu- opioid receptor (MOR) expression [24]. Opioids are known to modulate immune function and this confound is likely to worsen the pathogenesis and neurological complications of HIV-1 [20,44-6,66,74]. The viral coat glycoprotein of HIV-1, gp120, is an established neurotoxin that is required for viral entry and infection, and its extracellular actions are toxic to neurons and glia (microglia and astrocytes) in vitro and in vivo in both human and rodent models [4,5,9,11,12,15,17,19,35,50,51, 60,61,70]. Our lab and others have demonstrated how opioids potentiate this gp120 induced neurotoxicity [1,28,45]. We have shown that gp120 increases caspase-3 activity and induces apoptosis of striatal neurons. We are interested in better understanding how opioids affect HIV-gp120 induced neurotoxicity within the striatum and specifically want to investigate the role of caspase-3 in both glial and neuronal mediated mechanisms of neurotoxicity. Studies are proposed to determine if glial caspase-3 mediates gp120 neurotoxicity 1 opioids, and to establish whether opioids act via caspase-3 to directly affect neuron injury and/or death in vitro using caspase-3 knockout cells. Finally, we wil employ the use of caspase-3 knockout mice to investigate how genome-wide deletion of the executioner caspase will affect glial and neuronal responses after gp120 1 opioids in vivo. Collectively, the proposed studies will add to the understanding of how caspase-3 plays a role in the interactive co-morbidity of gp120 and opioids in regards to HIV neuropathogenesis. With this information, a better understanding of underlying mechanisms are made possible which lead to new options in therapeutics, which have ramifications for opioid abusers and users infected with HIV-1. PUBLIC HEALTH RELEVANCE: HIV-positive opioid drug abusers show an expedited progression to AIDS and since infected individuals are living longer with current antiretroviral therapy there is an increasing rate of HIV-associated neurocognitive disorders including dementia. Our research will help identify potential therapeutic agents for the prevention and treatment of neurocognitive dysfunction in HIV-positive individuals using and/or abusing opioids.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glial versus Neuronal Caspase-3 in Opioid-HIV gp120 Neurotoxicity
  • 批准号:
    8462462
  • 项目类别:
  • 资助金额:
    $3.42万
  • 财政年份:
    2012
  • 负责人:
    Kimberly Lynne Samano
  • 依托单位:
海外基金